Screener / SEC EDGAR /CIK 0001159036 /10-K filed Feb 17, 2026, compared with Feb 18, 2025 /Numbers from the XBRL of the 10-Ks
Nasdaq Health care · Biotechnology

Halozyme Therapeutics, Inc. HALO

Compare with peers Embed
Why it changed

The biggest changes in the 10-K filed Feb 17, 2026, in management's words

10-K, Item 7

This fiscal year against the last, and the sentences in the MD&A where management explains each change. Tickdelta picks sentences that name the line, a direction and a cause. It does not write explanations of its own.

Operating margin

Big change, FY to Dec 31, 2025 vs Dec 31, 2024

54.3% to 33.6% (-20.7 pts)

“The increase in research and development expense was primarily due to the acquisition of Elektrofi and Surf Bio, partially offset by lower compensation expense driven by resource optimization, labor allocation initiatives, and timing of planned investments in ENHANZE related to the development of our new high-yield rHuPH20 manufacturing process.”

Read it in the 10-K

Revenue

Big change, FY to Dec 31, 2025 vs Dec 31, 2024

+37.6%

“The increase in product sales, net was primarily due to increased sales of bulk rHuPH20 driven by partner demand as well as contributions from our proprietary product XYOSTED driven by continued market penetration, partially offset by lower device partnered product sales.”

Read it in the 10-K

“The increase in revenues under collaborative agreements was primarily due to the timing of milestones achieved.”

Read it in the 10-K

Cash from operations

Big change, FY to Dec 31, 2025 vs Dec 31, 2024

+36.0%

“The increase in net cash provided by operations was primarily due to an increase in revenue, partially offset by higher working capital spend.”

Read it in the 10-K

Net income

Big change, FY to Dec 31, 2025 vs Dec 31, 2024

-28.6%

“The decrease in investment and other income, net was primarily due to a decrease in the average invested balance and lower market interest rates.”

Read it in the 10-K

What management said, year by year

The cause given in each 10-K, 2 fiscal years, newest first · MD&A (Item 7)

Each bar is how the line changed that year (from the same 10-K's XBRL). Under it, the sentence in that year's MD&A that names the line, a direction and a cause, word for word. A year with no sentence says so.

Revenue

2 of 2 years explained
  • FY 2025 +37.6%

    “The increase in product sales, net was primarily due to increased sales of bulk rHuPH20 driven by partner demand as well as contributions from our proprietary product XYOSTED driven by continued market penetration, partially offset by lower device partnered product sales.”

    Read it in the FY 2025 10-K

    “The increase in revenues under collaborative agreements was primarily due to the timing of milestones achieved.”

    Read it in the FY 2025 10-K
  • FY 2024 +22.4%

    “The increase in product sales, net was primarily due to contributions from our proprietary products driven by continued market penetration, partially offset by lower sales of bulk rHuPH20 driven by the lower cost of the product which is passed on to partners and the timing of partner demand, and device partnered products driven by the timing of partner demand.”

    Read it in the FY 2024 10-K

    “The decrease in cost of sales was primarily due to lower bulk rHuPH20 and device sales, partially offset by higher proprietary product sales.”

    Read it in the FY 2024 10-K

Operating margin

2 of 2 years explained
  • FY 2025 -20.7 pts

    “The increase in research and development expense was primarily due to the acquisition of Elektrofi and Surf Bio, partially offset by lower compensation expense driven by resource optimization, labor allocation initiatives, and timing of planned investments in ENHANZE related to the development of our new high-yield rHuPH20 manufacturing process.”

    Read it in the FY 2025 10-K
  • FY 2024 +13.6 pts

    “The increase in research and development expense was primarily due to planned investments in ENHANZE related to the development of our new high-yield rHuPH20 manufacturing processes.”

    Read it in the FY 2024 10-K

Net income

2 of 2 years explained
  • FY 2025 -28.6%

    “The decrease in investment and other income, net was primarily due to a decrease in the average invested balance and lower market interest rates.”

    Read it in the FY 2025 10-K
  • FY 2024 +57.7%

    “The increase in investment and other income, net was primarily due to an increase in the average invested balance, partially offset by lower market interest rates.”

    Read it in the FY 2024 10-K

Cash from operations

2 of 2 years explained
  • FY 2025 +36.0%

    “The increase in net cash provided by operations was primarily due to an increase in revenue, partially offset by higher working capital spend.”

    Read it in the FY 2025 10-K
  • FY 2024 +23.3%

    “The increase in net cash provided by operations was primarily due to an increase in revenue, partially offset by higher working capital spend.”

    Read it in the FY 2024 10-K

Changes are computed from the XBRL figures in the same 10-K. Hover a number to see the line item. Open the 10-K

Sources

The Management's Discussion and Analysis (Item 7) of the latest 10-K, quoted word for word; the changes are computed from the same 10-K's XBRL.

Also

Financials: the numbers year by year.

Work with it

Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/HALO/export.csv") into a cell.

Next:Accounting checks
Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.